4577 — Daito Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeSmall CapNeutral

Annual income statement for Daito Pharmaceutical Co, fiscal year end - May 31st, JPY millions except per share, conversion factor applied.

	2020 May 31st	2021 May 31st	2022 May 31st	2023 May 31st	2024 May 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	44,991	48,715	43,464	45,101	46,895
Cost of Revenue
Gross Profit	9,479	10,798	11,459	10,331	9,839
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	39,652	43,005	37,166	39,920	43,032
Operating Profit	5,340	5,710	6,298	5,181	3,863
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	5,595	5,874	6,720	5,076	4,218
Provision for Income Taxes
Net Income After Taxes	3,925	4,157	4,628	3,527	3,178
Minority Interest
Net Income Before Extraordinary Items
Net Income	3,945	4,246	4,668	3,599	3,294
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3,945	4,246	4,668	3,600	3,295
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	281	292	316	229	211
Dividends per Share
Special Dividends per Share